Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
about
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerOvercoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug CombinationsThe therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerSuberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell lineYU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsA radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 CellsRNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrityEvaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Olaparib: first global approval.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?PARP inhibitors as antitumor agents: a patent update (2013-2015).Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.PARP inhibitors: the journey from research hypothesis to clinical approval.MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells.Interplay of Histone Marks with Serine ADP-RibosylationNovel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
P2860
Q26783551-723F3E24-2313-4DA6-ABD6-E09E565C8E9CQ28552235-D65A53B9-E01E-4833-AFE8-F88BE433B9D6Q33659166-BE40AF23-1CF8-4F7B-A4ED-1C54121AC34CQ35232590-7E3AF209-80FF-4AD9-AD2D-1C133A8C638DQ35676066-C67CBD39-CDC5-48A6-A032-4A78C524BB22Q35940003-19F219BC-1FC6-4ACB-A866-5F2833E62F84Q35977483-32DC450F-E9CF-4884-BD0B-22AD4793F0C7Q36096420-7ABC3649-0B10-4B9C-A6EF-2237FEC0019CQ36203280-CFEB7E7D-77EA-4091-9920-90631D3D319AQ36517161-A65A28C7-4DAB-457F-A605-0981708D949AQ36945532-D457C742-BD59-469C-ADCE-54866DA835D9Q37158437-12D6A539-61A3-4B8E-BF29-F044314A2629Q38330356-90A1EDF6-4E84-4557-A98E-77B64EFC357EQ38344675-48FC5B8A-53BB-4AA2-B744-EA1786A748F2Q38433579-C3DC61C6-C756-4DD0-8A8E-8DBC56903A37Q38756596-A91EC924-49AF-4D7A-9635-4FA95B2EEFD3Q38777616-1CE41350-4BB0-419F-BEB1-F6F693E73463Q38795712-0A7E5C80-AB97-4CAE-80DD-517C2F35D13EQ38907017-92B78A05-5DBC-4186-ACEF-6E49DC729560Q40078610-B2DCF11C-4237-4F53-9D72-4CED62DC20BCQ41088379-D5315264-102F-4807-ADF6-B92401E074BFQ48119543-F3A8E599-AA50-4BE2-A7E3-760B6AC16F83Q48158007-6877F3FB-3A52-424A-9D0C-C4C44A69F50CQ48698494-8E4D664F-8506-4BC3-8130-361698DFB89CQ51757810-448E0522-618B-40EC-BD17-E4B1B2F9605DQ52642120-EF18B588-4309-4AD3-BA96-F42C62D5D216Q53682668-D97F9E20-9940-4E16-9DF9-8B8E3AB60337Q55398218-9DE1E93B-322B-48F0-AE84-7A90A2C0F326Q58697556-ECEB53B6-E67D-43F0-BE13-C0ED00FC2817Q59138142-91073A7B-4E90-4EC3-8B3E-1D7720EAA6F9
P2860
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@ast
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@en
type
label
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@ast
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@en
prefLabel
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@ast
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@en
P2093
P2860
P1433
P1476
Suberoylanilide hydroxamic aci ...... DNA repair in ovarian cancer.
@en
P2093
Andrew J Wilson
Dineo Khabele
Erica Wass
Jeanette Saskowski
Panagiotis A Konstantinopoulos
P2860
P304
P356
10.1016/J.YGYNO.2014.03.007
P407
P577
2014-03-11T00:00:00Z